Introduction
The immune system activity was long considered detrimental in the context of CNS diseases. Due to cellular heterogeneity, impossible to dissect with available research tools, the roles of different immune cell subsets in neurodegeneration onset and progression were poorly understood (Keren-Shaul et al., 2017) . In this context, microglia, the resident macrophages of the brain and spinal cord, have been widely viewed as a homogeneous population of cells involved in CNS development and important for steady-state brain maintenance, which, nevertheless, ''lose control'' and become destructive to the CNS under neurodegenerative conditions (Crotti and Ransohoff, 2016; Heneka et al., 2015) . Recently, comprehensive single-cell RNA analysis of CNS immune cells in neurodegenerative conditions discovered disease-associated microglia (DAM), a subset of microglia showing a unique transcriptional and functional signature (Keren-Shaul et al., 2017) . DAM are associated with expression of genes-many of which were found in human genome-wide association studies (GWASs) as linked to Alzheimer's disease (AD) and other neurodegenerative conditions-including TREM2, a receptor required for DAM activation (Keren-Shaul et al., 2017; Lambert et al., 2013; Yeh et al., 2017) . Studies in mouse models of neurodegenerative diseases with deficiency in TREM2 demonstrated that its signaling is essential for microglia to detect and respond to neurodegeneration cues Wang et al., 2015) .
Emergence of DAM as players in brain disease may shed a new light on the conflicting views regarding the detrimental or beneficial role of microglia that have arisen in recent years (Aguzzi et al., 2013) . Further investigation is urgently needed to better understand the sensory mechanisms, signaling pathways, and regulatory checkpoints of DAM, as well as their involvement in brain diseases. We propose that microglia display a dedicated sensory mechanism to detect neural tissue damage in the form of neurodegeneration-associated molecular patterns (NAMPs), a model analogical to the peripheral immune system's pathogen-and damage-associated stress signals (PAMPs and DAMPs). Further, using the analogy to pathogen sensing, which initiates innate immune responses outside the brain, deep molecular profiling of DAM cells, and comparison to human GWAS studies, we speculate on the role of DAM in CNS pathologies. Finally, we discuss the therapeutic potential of modulating DAM function in CNS diseases.
however, their characteristics were since then further validated in other amyloid-b (Ab) AD mouse models, such as the PS2APP and APP/PS1 (Ajami et al., 2018; Friedman et al., 2018; Holtman et al., 2015; Kamphuis et al., 2016; Krasemann et al., 2017; Mrdjen et al., 2018; Ofengeim et al., 2017) . Importantly, DAM were primarily detected in the CNS regions affected by the disease, but not in other regions. In 5XFAD and APP/PS1 models of AD, DAM co-localized with Ab plaques in the cortex and were absent from the cerebellum, where Ab plaques do not occur (Keren-Shaul et al., 2017; Mrdjen et al., 2018) . Further investigation had led to the discovery of DAM or a DAM-like phenotype in tauopathy models Tau P301L and Tau P301S (Friedman et al., 2018; Leyns et al., 2017) and other neurodegenerative diseases, such as ALS (Chiu et al., 2013; Friedman et al., 2018; Holtman et al., 2015; Keren-Shaul et al., 2017; Krasemann et al., 2017; Spiller et al., 2018) and multiple sclerosis (MS; (Krasemann et al., 2017) , as well as in aging (Holtman et al., 2015; Keren-Shaul et al., 2017; Mrdjen et al., 2018; Olah et al., 2018) , and in mouse models of severe neurodegeneration, such as CK-p25 (Mathys et al., 2017) . Markers of a DAM signature were also observed in human AD postmortem brains (Friedman et al., 2018; Keren-Shaul et al., 2017) . These compelling observations led us to propose that the DAM phenotype is a common signature of microglial response to CNS pathology, irrespective of the disease etiology.
Analysis of microglia from 5XFAD and APP/PS1 mice deficient in TREM2 revealed that DAM differentiation is a sequential two-step process (Figure 1 ). The stage 1 DAM transition is required for further activation of the stage 2 DAM program (Friedman et al., 2018; Keren-Shaul et al., 2017) . While transition from stage 1 to stage 2 DAM requires a TREM2 signal, the transition from homeostatic microglia to stage 1 DAM is TREM-independent, and factors mediating this step are currently unknown. TREM2-independent signaling initiates the marked downregulation of homeostatic microglia genes (Cx3cr1, P2ry12) and is associated with upregulation of the TREM2 regulators/adaptors Tyrobp and Apoe. On the other hand, the TREM2-dependent signaling involves upregulation of the lysosomal, phagocytic, and lipid metabolism pathways (such as Lpl, Cst7, and Axl). How does TREM2 signaling promote phenotypic transition from stage 1 to stage 2 DAM? Several hypotheses can be proposed: (1) TREM2 may sustain microglia activation induced by other receptors in stage 1, or (2) TREM2 signaling may initiate a stage-2-specific transcriptional program. Recent data support the first hypothesis: TREM2 has been shown to have pro-proliferative and pro-survival function through PI-3K, b-catenin, and mTOR pathways (Otero et al., 2009; Peng et al., 2010; Ulland et al., 2017) , suggesting a role for TREM2 in sustaining microglia activation and survival rather than promoting additional transcriptional programs. However, further studies are needed to resolve the mechanisms of DAM regulation. Future experiments using single-cell RNA analysis will verify whether the transcriptional profiles of DAM in other disease models are identical with DAM signature found initially in 5XFAD and mSOD1(ALS) mouse models or whether there are various disease-specific subtypes of DAM.
DAM: Sensors of Neurodegeneration-Associated Molecular Patterns
The identification of sensors and molecular mechanisms of pathogen detection was a turning point in immunology (Janeway, 1989; Lemaitre et al., 1996; Poltorak et al., 1998) . After the initial discovery of Toll-like receptor 4 (TLR-4) it became apparent that various stress signals known as PAMPs and DAMPs are recognized via pattern recognition receptors (PRRs) to initiate a defense response (Janeway, 1989; Matzinger, 1994) . PRRs detect shared features of whole groups of various pathogens and stress signals (patterns), enabling a relatively small number of sensors to cover a broad spectrum of dangers. For example, diverse Gram-negative bacteria are recognized by TLR-4, a receptor sensitive to lipopolysaccharide (LPS) in the outer bacterial membrane; stimulated TLR-4 then elicits responses to protect the tissue and organism from bacterial threats. In addition, even various immune stimuli engaging different receptors can induce a similar protective response via converging intracellular signaling; for example, both single-stranded RNA (recognized by TLR-7/8, RIG-I, and more) and unmethylated CpG motifs (recognized by TLR-9) elicit interferon type I. Response to such triggers is protective against the pathogen or spread of damage but can simultaneously lead to dysregulation of tissue function (Matzinger and Kamala, 2011) .
We propose that induction of the DAM phenotype, shared across various neurodegenerative diseases, is a specific case of this fundamental principle. Accordingly, neurodegenerationassociated molecular patterns (NAMPs), danger signals that are commonly present in various CNS conditions, are recognized by a battery of receptors constitutively expressed on microglia and trigger their transition into DAM, whose primary function is to contain and remove the damage (Figure 2 ). The NAMPs include danger molecules present on apoptotic bodies of dying neural cells, myelin debris, lipid degradation products, extracellular protein aggregates typical for neurodegenerative diseases and aging (e.g., Ab), and other known danger signals specifically relevant in the CNS environment (e.g., extracellular purines).
DAM appear under conditions of accumulation of neuronal apoptotic bodies and myelin debris (ALS, AD, aging, demyelination) (Keren-Shaul et al., 2017; Krasemann et al., 2017; Poliani et al., 2015; Wang et al., 2015) . Further, injection of labeled apoptotic neurons into the brain of naive mice elicits emergence of phagocytic microglia, which engulf cell debris and show transcriptomic changes identical with DAM cells (ApoE hi Clec7a hi Tmem119 low P2Y12 low ). This effect is largely abrogated by annexin V-mediated blockade of phosphatidylserine (PtdSer), which is exposed on the surface of apoptotic cells (Krasemann et al., 2017; Wang et al., 2015) , suggesting that appearance of cell death in the CNS precedes emergence of DAM and that PtdSer can be important for their induction. In vitro studies using the NFAT-GFP reporter cell line identified TREM2, a key player in DAM phenotype induction, as a direct receptor of several damage-related signals, including PtdSer and glycolipids sphingomyelin and sulfatide, released from damaged myelin (Poliani et al., 2015; Wang et al., 2015) . Accordingly, injection of apoptotic neurons to mice deficient in Trem2 largely abrogated induction of the DAM phenotype but, interestingly, did not inhibit phagocytic activity of microglia surrounding the injection site (Krasemann et al., 2017) . Similarly, microglia deficient in Microglia are equipped with a mechanism to sense neuronal damage (NAMPs) via a specific set of receptors (including TREM2, purinergic receptors, and possibly others) in analogy to the peripheral immune system pathogen-and damage-associated stress signals (PAMPs and DAMPs) detected via PRRs.
TREM2 engulfed apoptotic cells as efficiently as their wild-type counterparts in vitro , highlighting the possibilty, that TREM2 and DAM display additional roles in neurodegeneration beyond engulfment of debris and misfolded proteins. The Tyro3/Axl/Mer (TAM) receptor tyrosine kinases, with their bound protein ligands (Gas6 and Pros1), also recognize PtdSer on apoptotic cell membranes (Lemke, 2017) . Axl is dramatically upregulated in DAM compared to homeostatic microglia in the 5xFAD model of AD and mSOD1 model of ALS and in microglia from pathologically affected areas of the Thy1-SNCA A53T model of neurodegeneration (Fourgeaud et al., 2016; Keren-Shaul et al., 2017) . TAM receptors are involved in regulation of clearance of apoptotic cells in parallel to repressing inflammation in the context of neurogenesis and laser-induced lesions; future research will determine the role of TAM as a NAMPs sensor in the degenerating CNS. In AD brains, DAM associate with Ab plaques, and TREM2 was found to bind Ab with nanomolar affinity in vitro Zhong et al., 2018) . In addition, TREM2 signaling was activated in TREM2-NFAT reporter cells by an array of negatively charged phospholipids, including phosphatidylinositol, phosphatidylcholine, and possibly others, which associate with Ab and accumulate in the brain during Ab deposition (Ahyayauch et al., 2012; Nagarathinam et al., 2013; Wang et al., 2015) . Moreover, TREM2 was found to bind lipoproteins (ApoE, LDL, CLU/apoj), which form complexes with Ab aggregates, facilitating their uptake by microglia Terwel et al., 2011; Yeh et al., 2016) . This broad spectrum of ligands makes TREM2 a bona fide PRR of CNS damage. Importantly, rare human variants of TREM2 associated with higher risk of neurodegenerative disease showed impaired binding of many of these ligands in vitro and in vivo (Song et al., , 2018 Wang et al., 2015; Yeh et al., 2016; Zhao et al., 2018) .
Induction of stage 1 DAM is associated with decreased expression of a purinergic receptor, P2Y12, which recognizes extracellular ADP, another universal danger signal in the CNS (Keren-Shaul et al., 2017; Rodrigues et al., 2015) . Purine microgradients are created by dying cells in the CNS under physiological conditions, upon tissue injury or hyperactivity of neuronal networks (e.g., in epilepsy), and serve as ''find me'' signals to induce microglial chemotaxis toward the stressed region and phagocytosis of cell debris (Abiega et al., 2016; Davalos et al., 2005) . The role of extracellular ADP, UDP, and other nucleotides in DAM induction remains unexplored, but based on a broad literature on these factors as danger signals in the brains, they are likely to be involved in shaping DAM responses in neurodegenerative diseases (Rodrigues et al., 2015) .
NAMP-dependent induction of DAM is only one aspect of the complex mechanisms of neurodegenerative diseases that spans loss of blood-brain barrier integrity, alterations in the peripheral immune system, and dysregulated function of other brain cells (Mosher and Wyss-Coray, 2014) . Microglia, as sentinels, may sense these changes in their environment. In this context, it is interesting to consider how death of a specific subtypes of CNS cells could modulate the DAM phenotype; for instance, Parkinson's disease is associated with death of dopaminergic neurons only. Microglia express neurotransmitter receptors (such as GABA, glutamate, adrenaline, and dopamine) and can respond to them by adopting a range of immune phenotypes depending on the neurotransmitter involved and the specific receptor activated (Lee, 2013; Pocock and Kettenmann, 2007) .
Similar to the peripheral immune system, where immune activation may have deleterious consequences to the surrounding tissue if it is not counterbalanced by negative regulators, microglia are equipped with a set of restraining mechanisms-for example, CX 3 CR1 and CD200 molecules-which upon interaction with their ligands promote microglial homeostatic state upon challenge (Biber et al., 2007) . Thereby these inhibitory checkpoints can possibly compete with activating NAMP signaling and transition to DAM (Deczkowska et al., 2018) . Accordingly, expression of CX 3 CR1 and CD200 molecules is decreased in stage 1 DAM, which may suggest that blocking certain restraining mechanisms may be a prerequisite for acquisition of the DAM phenotype (Keren-Shaul et al., 2017) . In addition, evidence exists that mice deficient in CX 3 CR1 show diminished Ab pathology, but loss of CX 3 CR1 was shown to have a varying effect on cognitive ability and neuronal death, suggesting that sensitizing microglia to NAMPs present in AD brain may stimulate phagocytic activity but may also be associated with potentially detrimental side effects (Lee et al., 2010; Wolf et al., 2013) .
A recent study proposed that TDP-43 is a neurodegenerationrelated factor that may inhibit phagocytic function of DAM (Spiller et al., 2018) . In this study, in a model of TDP-43-mediated ALS-like neurodegeneration, microglia undergo only minor phenotypic changes, but blocking the expression of pathological TDP-43 in this model causes microglial activation. Depleting microglia using CSF1R inhibitor in the early recovery phase suppressed the ability to restore the motor function, demonstrating the protective role of microglia in this context. During late stage of the disease and the recovery stage after the pathological TDP-43 had been removed, the microglia showed DAM-like transcriptional profiles, including elevated expression of ApoE, Lpl, Ctsb, and Itgax, but microglial activation and clearance of TDP-43 took place only after its expression had been stopped. In this regard, it would be important to find out whether in this model DAM occur as a subset of microglia involved in the recovery process and whether suppression or perturbation of DAM activity is common in neurodegenerative conditions.
Another important aspect of neurodegenerative diseases that is often not reproduced in animal models is aging (Galatro et al., 2017) , a process that impacts various facets of CNS function, including decreased phagocytic activity (Safaiyan et al., 2016) and lowered threshold of microglial activation by immune stimuli known as ''microglia priming'' (Deczkowska et al., 2017; Niraula et al., 2017; Perry and Holmes, 2014) . As chromatin analysis showed that microglia are ''prepared'' for quick transition to DAM upon need, aging-related dysregulation of transcription factors and chromatin modifiers in microglia may hamper their transformation to DAM in old age (Deczkowska et al., 2017; Keren-Shaul et al., 2017) . In summary, identification of specific NAMPs and their receptors, as well as their positive and negative regulators alongside development of pharmacological agonists and antagonists, would greatly advance our understanding of a universal molecular basis for CNS disease and possibly reveal new therapeutic opportunities.
DAM in the Context of Human Susceptibility to Neurodegeneration
Large numbers of AD-associated loci have been identified using GWASs over the last years. Strikingly, multiple risk variants of late-onset AD are related to genes specifically expressed by myeloid cells, including microglia and monocyte-derived macrophages, emphasizing the pivotal role of the innate immune system in neurodegeneration (Lambert et al., 2013) . The challenge beyond identifying susceptibility genes is to understand the mechanism through which these variants shape the CNS pathology.
Examining the expression dynamics of several risk genes in the stepwise transition from homeostatic microglia to DAM strongly ascribes a positive and protective role for DAM in AD pathology (Figure 3) . The major risk factor allele, APOE-ε4, which accounts for up to 50% of cases for late-onset familial AD (Liu et al., 2013; Strittmatter et al., 1993) , is one of the earliest (TREM-independent) upregulated genes in DAM, with a 25-fold increase compared to homeostatic microglia (Keren-Shaul et al., 2017) . Another compelling piece of evidence that dysfunctional microglia may contribute to AD stemmed from the finding of the rare mutation (R47H) in TREM2 that leads to a 3-to 4-fold increased risk of AD (Guerreiro et al., 2013; Jonsson et al., 2013) . A recent study by Song et al. introduced the human version of TREM2 carrying the R47H mutation into 5XFAD mice and demonstrated an impaired function of microglia (Song et al., 2018) . As TREM2 is necessary for full activation of the DAM program in mice, these findings support the idea that DAM function may protect from disease development. Further, TYROBP, also known as DAP12, which forms a receptor-signaling complex with TREM2, is also upregulated in DAM and is linked to presenile dementia (Paloneva et al., 2000) . Another gene that shows increased expression in DAM cells is progranulin (GRN) (KerenShaul et al., 2017) , a secreted growth factor involved in the regulation of multiple processes, including development, wound healing, and inflammation (Baker et al., 2006) . GRN mutations explain up to 20% of familial and 5% of sporadic frontotemporal dementia (FTD) cases; importantly, all pathologic GRN mutations reduce progranulin levels or result in loss of function (Baker et al., 2006) ; therefore, increased GRN transcription in DAM further suggests their protective role.
The transmembrane receptor CD33 is a risk factor for AD that exhibits 3-fold downregulation during DAM activation. CD33 overexpression through a polymorphism in the promoter region (rs3865444C) was linked to increased AD risk, while other SNPs (rs3865444A and rs12459419T) that yield a non-functional CD33 protein by alternative splicing were described as protective alleles (Griciuc et al., 2013; Malik et al., 2013) . Both the protective and detrimental mutations in CD33 point toward the importance of downregulating CD33 function to improve AD pathology. MS4A6A is another example of a signaling receptor linked to AD and downregulated in DAM (4-fold). Importantly, all MS4A6A risk variants increase its expression, suggesting that microglia of patients with the susceptibility allele may be unable to decrease MS4A6A expression sufficiently, yielding dysfunctional DAM (Proitsi et al., 2014) . Mutations in BIN1, PICALM, and PLCG2 are also protective factors for AD, all downregulated during the homeostatic-to-DAM transition (Sims et al., 2017; Tan et al., 2013; Xu et al., 2015) .
The examples above show a remarkable trend where loss-offunction mutations of the DAM-upregulated genes are linked to elevated risk of developing AD. Conversely, gain-of-function Mutations in certain genes (identified by GWAS) were shown to increase the risk of Alzheimer's disease (upper panel) while others were found as protective factors (lower panel). These factors were found to be highly correlated to the DAM phenotype (red arrow represents upregulation, blue arrow represents downregulation). Numbers (expressed as x-fold) represent the fold change of expression in the DAM versus homeostatic microglia (Keren-Shaul et al., 2017) . Mutation indicates loss of function unless marked otherwise. LOF, loss of function; GOF, gain of function. mutations in DAM-downregulated genes increase susceptibility to AD. Taken together, accumulating evidence from human genetics studies provide strong evidence to propose that the DAM program is a protective innate immune response against AD pathology.
Using mice deficient in genes involved in the DAM phenotype, as well as in-depth analysis of human patients carrying mutations in DAM-related genes, will illuminate the role of DAM in specific disease contexts. For example, CX 3 CR1 deficiency alters microglial activation and reduces Ab deposition in APP/PS1, R1.40, and CRND8 AD mouse models (Lee et al., 2010; Liu et al., 2010) but exacerbates the disease pathology in a tau-driven AD model (Bhaskar et al., 2010) . TREM2 deletion in P301S-tau model exacerbated the disease outcome (Jiang et al., 2016) , while studies of TREM2 deficiency in models of Ab pathology (5XFAD or APP/PS1) showed conflicting results, suggesting that the outcome of DAM presence may depend on the disease stage (Jay et al., 2017) . Recent study used a humanized TREM2 mouse model crossed to a 5XFAD mouse and showed that the risk factor mutation R47H decreases microglial interaction with Ab plaques in AD animals, but the study did not evaluate the AD pathology in terms of plaque burden or cognitive ability (Song et al., 2018) .
DAM Biology and Therapeutics: Challenges and Opportunities
Accumulating evidence shows that microglia have developed a set of sensory mechanisms to detect any deviation from homeostasis in the CNS. Similar to the resident macrophages in other tissues, microglial response to danger-associated triggers, NAMPs, might be counterbalanced by co-occurring inhibitory signals. In principle, the DAM response arises as a protective mechanism aiming to contain and remove the neuronal damage. The universal disease-associated subset of microglia, found in various CNS conditions, seems to provide a central piece in the neurodegenerative disease puzzle (Aguzzi et al., 2013) ; nevertheless, many questions remain to be answered.
For example, microglial phagocytosis and complement cascade were linked to synaptic pruning, a physiological part of CNS development (Schafer et al., 2012; Stevens et al., 2007) . Analysis of mouse models and human tissue suggests that in AD, this developmental mechanism is aberrantly and excessively re-activated; microglia take up viable synapses, leading to memory loss (Hong et al., 2016) . Microglia depletion using CSF1R blockade in Ab models leads to an increased plaque size but protects against synapse loss and rescues behavioral deficits (Dagher et al., 2015; Olmos-Alonso et al., 2016; Spangenberg et al., 2016) . In addition, microglia depletion also prevented neuronal loss in animal models of ALS and tau propagation in a model of tau pathology (Asai et al., 2015; Martínez-Muriana et al., 2016) . In all these cases, the treatment led to ablation of all microglia without distinction between the disease-associated and homeostatic; specific roles of DAM in the process of synapse clearance and neuronal loss under neurodegenerative conditions need to be further explored. As molecular markers best correlated with AD-associated cognitive impairment are tau pathology and synapse loss (Jack et al., 2010) , these questions must be thoroughly studied before designing DAM-boosting strategies for AD.
In addition, it has been shown that activation of microglia through the NLRP3 inflammasome promotes Ab accumulation. The inflammasome is known to activate a unique inflammatory pathway that leads to release of IL-1b (Heneka et al., 2013) and the inflammasome component ASC, which forms large polymeric protein complexes called ASC specks that directly associate with Ab plaque cores, facilitating plaque deposition (Venegas et al., 2017) . These results suggest that microglial detection of Ab may actually amplify Ab deposition. However, TREM2 signaling was proposed to inhibit pro-inflammatory signaling (Hamerman et al., 2005; Turnbull et al., 2006) . It is possible that Ab induces protective DAM early on during disease progression, whereas at late stages, when the accumulation of plaques activates the inflammasome in microglia, DAM become dysregulated and accelerate the disease. This hypothesis is supported by a recent study on TREM2-deficient APP/PS1 mice, showing a disease stage-dependent effect of TREM2 deletion on Ab deposition and inflammatory conditions in the brain (Jay et al., 2017) .
In light of these observations, boosting DAM activity in early disease stages, or prophylactically before the disease occurs at all, may present a promising strategy to fight any hallmark of neurodegeneration as soon as it appears, preventing accumulation of the CNS damage (McDade and Bateman, 2017) . The link between protective gene variants in AD and transcriptomic DAM signature (Figure 3 ) supports this direction of future research. The effect of DAM presence in later stages of neurodegeneration is much less understood, and this important aspect cannot be elucidated without animal models more accurately reflecting human diseases. Further, as other factors like gender, microbiome, and systemic exposure to immune signals can affect microglia in steady state and were proposed to influence the risk of neurodegenerative disease occurrence and progression, these are also likely to modulate DAM (Knuesel et al., 2014; May, 2016; Quigley, 2017; Thion et al., 2018; Wendeln et al., 2018) .
AD is a heterogeneous disease in which multiple detrimental factors contribute to cognitive loss and disease escalation. Therefore, targeting any single factor (e.g., Ab, tau, neuroinflammation etc.), even if successful, is not sufficient to modify the disease, and thus, there is a desperate need for new, more comprehensive approaches (McDade and Bateman, 2017) . Boosting the intrinsic protective mechanism may constitute a more comprehensive therapy that is independent of the disease etiology. Such a holistic approach has worked effectively in various types of cancers (Pardoll, 2012; Sharma and Allison, 2015) and has created the basis for using immune checkpoint blockade in AD (Baruch et al., 2016) .
The discovery of DAM created an opportunity to develop a therapy targeting the universal and intrinsic mechanism of fighting against neuronal death shared across multiple neurodegenerative conditions. Intensive research will be needed to better understand the DAM induction mechanisms and their effect on various aspects of CNS pathology to make effective use of their promising therapeutic potential. 
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